Literature DB >> 26183543

Discovery of potent and selective nonplanar tankyrase inhibiting nicotinamide mimics.

Yves Nkizinkiko1, B V S Suneel Kumar2, Variam Ullas Jeankumar2, Teemu Haikarainen1, Jarkko Koivunen1, Chanduri Madhuri2, Perumal Yogeeswari2, Harikanth Venkannagari1, Ezeogo Obaji1, Taina Pihlajaniemi1, Dharmarajan Sriram3, Lari Lehtiö4.   

Abstract

Diphtheria toxin-like ADP-ribosyltransferases catalyse a posttranslational modification, ADP-ribosylation and form a protein family of 17 members in humans. Two of the family members, tankyrases 1 and 2, are involved in several cellular processes including mitosis and Wnt/β-catenin signalling pathway. They are often over-expressed in cancer cells and have been linked with the survival of cancer cells making them potential therapeutic targets. In this study, we identified nine tankyrase inhibitors through virtual and in vitro screening. Crystal structures of tankyrase 2 with the compounds showed that they bind to the nicotinamide binding site of the catalytic domain. Based on the co-crystal structures we designed and synthesized a series of tetrahydroquinazolin-4-one and pyridopyrimidin-4-one analogs and were subsequently able to improve the potency of a hit compound almost 100-fold (from 11 μM to 150 nM). The most potent compounds were selective towards tankyrases over a panel of other human ARTD enzymes. They also inhibited Wnt/β-catenin pathway in a cell-based reporter assay demonstrating the potential usefulness of the identified new scaffolds for further development.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cancer; Inhibition; Poly(ADP-ribose)polymerase; Protein crystallography; Tankyrase; Virtual screening; Wnt-signalling

Mesh:

Substances:

Year:  2015        PMID: 26183543     DOI: 10.1016/j.bmc.2015.06.063

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  8 in total

Review 1.  2,3-Dihydroquinazolin-4(1H)-one as a privileged scaffold in drug design.

Authors:  Mariateresa Badolato; Francesca Aiello; Nouri Neamati
Journal:  RSC Adv       Date:  2018-06-07       Impact factor: 4.036

2.  3D-QSAR, Docking, ADME/Tox studies on Flavone analogs reveal anticancer activity through Tankyrase inhibition.

Authors:  Sarfaraz Alam; Feroz Khan
Journal:  Sci Rep       Date:  2019-04-01       Impact factor: 4.379

3.  2-Phenylquinazolinones as dual-activity tankyrase-kinase inhibitors.

Authors:  Yves Nkizinkiko; Jenny Desantis; Jarkko Koivunen; Teemu Haikarainen; Sudarshan Murthy; Luca Sancineto; Serena Massari; Federica Ianni; Ezeogo Obaji; Maria I Loza; Taina Pihlajaniemi; Jose Brea; Oriana Tabarrini; Lari Lehtiö
Journal:  Sci Rep       Date:  2018-01-26       Impact factor: 4.379

Review 4.  Regulation of Wnt/β-catenin signalling by tankyrase-dependent poly(ADP-ribosyl)ation and scaffolding.

Authors:  Laura Mariotti; Katie Pollock; Sebastian Guettler
Journal:  Br J Pharmacol       Date:  2017-11-05       Impact factor: 8.739

5.  Discovery of Novel Inhibitor for WNT/β-Catenin Pathway by Tankyrase 1/2 Structure-Based Virtual Screening.

Authors:  Bo Li; Jinxia Liang; Feng Lu; Guandi Zeng; Jindao Zhang; Yinxing Ma; Peng Liu; Qin Wang; Qian Zhou; Liang Chen
Journal:  Molecules       Date:  2020-04-06       Impact factor: 4.411

6.  Preclinical Lead Optimization of a 1,2,4-Triazole Based Tankyrase Inhibitor.

Authors:  Jo Waaler; Ruben G G Leenders; Sven T Sowa; Shoshy Alam Brinch; Max Lycke; Piotr Nieczypor; Sjoerd Aertssen; Sudarshan Murthy; Albert Galera-Prat; Eddy Damen; Anita Wegert; Marc Nazaré; Lari Lehtiö; Stefan Krauss
Journal:  J Med Chem       Date:  2020-06-23       Impact factor: 7.446

7.  Combinatorial Virtual Screening Revealed a Novel Scaffold for TNKS Inhibition to Combat Colorectal Cancer.

Authors:  Chun-Chun Chang; Sheng-Feng Pan; Min-Huang Wu; Chun-Tse Cheng; Yan-Rui Su; Shinn-Jong Jiang; Hao-Jen Hsu
Journal:  Biomedicines       Date:  2022-01-10

8.  Development of a 1,2,4-Triazole-Based Lead Tankyrase Inhibitor: Part II.

Authors:  Ruben G G Leenders; Shoshy Alam Brinch; Sven T Sowa; Enya Amundsen-Isaksen; Albert Galera-Prat; Sudarshan Murthy; Sjoerd Aertssen; Johannes N Smits; Piotr Nieczypor; Eddy Damen; Anita Wegert; Marc Nazaré; Lari Lehtiö; Jo Waaler; Stefan Krauss
Journal:  J Med Chem       Date:  2021-12-08       Impact factor: 7.446

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.